SCP
AVEO

Sender Company & Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Sender Company & Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-92,026
Closed -$432K – 123
2021
Q4 		$432K Buy
+92,026
New +$571K 0.22% 77

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Sender Company & Partners's AVEO Position: Q1 2022 in Review

Sender Company & Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2022, closing a stake of 92,026 shares — an estimated $432K sold.

Sender Company & Partners first reported a position in AVEO in Q4 2021 and held it in 1 quarter. The position peaked at $432K in Q4 2021. 58 funds tracked by Wall St. Rank hold AVEO as of Q1 2022.

  • Sender Company & Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 92,026 AVEO Pharmaceuticals, Inc. shares in Q1 2022, an estimated $432K.
  • Sender Company & Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's AVEO Pharmaceuticals, Inc. position peaked at $432K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.